We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Merck gets ex- N. American rights to Cardiome's oral vernakalant; later gains WW rights; deal ends
07 Jan 2016
Executive Summary
Cardiovascular therapeutics developer Cardiome Pharma has granted Merck & Co. exclusive rights to its oral version of vernakalant, a Phase III drug candidate for atrial fibrillation (AF). The Merck Sharp & Dohme subsidiary received a global license (excluding the US, Canada, and Mexico) to the intravenous formulation.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Terminated
Deal Type
Alliance
Co-Promotion
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?